Orexigen Therapeutics CEO Discusses Q2 2012 Results - Earnings Call Transcript

Orexigen Therapeutics, Inc. (OREX)

Q2 2012 Earnings Call

August 7, 2012, 8:30 a.m. ET

Executives

Heather Turner – VP & General Counsel

Mike Narachi – President and CEO

Preston Klassen – SVP, Global Contrave Team

Jay Hagen – Chief Business Officer

Analysts

Charles Duncan – JMP Securities

Marko Kozul – Leerink Swann

Steve Byrne (Tazine) – BoA/Merrill Lynch

Christian Glennie – Edison Investments

Charles Duncan – JMP Securities

Presentation

Operator

Welcome to the Q2 2012 Orexigen Therapeutics, Inc. earnings conference call. My name is Lorraine and I will be your operator for today's call. (Operator Instructions).

I will now turn the call over Miss Heather Turner. Miss Tuner, you may begin.

Heather Turner

Hello, and thank you for joining us to discuss the company's second quarter 2012 financial results. I am joined on this call by Mike Narachi, Chief Executive Officer, Dr. Preston Klassen, Senior Vice President Development, Jay Hagen, Chief Business Officer, and McDavid Stilwell, Vice President of Corporate Communications and Business Development.

This morning, we issued a press release that provides details of the company's second quarter financial results. Please note that all of the information discussed on this call this morning is covered under the Safe Harbor provisions of the Private Securities Litigation Reform act. I caution listeners that during this call, the company's management will be making forward-looking statements. Actual results could differ materially from those stated or implied by our forward-looking statements due to risks and uncertainties associated with the company's business. These forward-looking statements are qualified in their entirety by the cautionary statements contained in today's press release and the company's SEC filings including the form 10-Q the company plans to file this week.

If you liked this article you might like

First Witness to Testify in Pharma Bro's Trial Felt 'Betrayed'

These 5 Stocks Under $10 Are Set to Soar Higher

5 Stocks Under $10 Set to Soar

Orexigen Therapeutics (OREX) Stock Plunges on Q4 Miss

8 Stocks Under $10 Making Big Moves Higher